Oppenheimer cuts price targets for EnerSys and Cormedix, keeps Outperform ratings
According to TradingView, Oppenheimer kept Outperform on EnerSys and Cormedix while lowering targets to $210 and $13, down 16.0% and 13.3% respectively.
- published on Newsmetry
- original source published
the same feed is available to bots and dashboards through the api. connect the api →
what happened
Oppenheimer kept its Outperform rating on EnerSys but reduced its price target to $210 from $250, a cut of 16.0%. Citing Benzinga data, TradingView reports that the new target implies 42.1% upside from the November 12 close of $147.80.
The firm also retained Outperform on Cormedix and lowered its target to $13 from $15, a 13.3% reduction. That level implies 168.6% upside from the November 12 close of $4.84.
why it matters
Analyst target changes of this kind concern individual stocks and rarely move the broader market. For investors they show how expectations for these shares are shifting, though the source does not describe the reasons behind either revision.
tags
instruments
sources
- Oppenheimer maintains EnerSys at Outperform, lowers price target to $210 from $250 — TradingView, 13 November 2026 at 15:35 UTC
- Oppenheimer maintains Cormedix at Outperform, lowers price target to $13 from $15 — TradingView, 13 November 2026 at 15:34 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
alerts on your topics, the morning digest and the api — in your account.
get stories in real time ↗